We are live on ! Find out more
WP

Woodline Partners Portfolio holdings

AUM $26.4B
1-Year Est. Return 44.85%
This Fund
S&P 500
This Quarter Est. Return
+13.68%
1 Year Est. Return
+44.85%
3 Year Est. Return
+131.23%
5 Year Est. Return
+174.12%
10 Year Est. Return
AUM
$7.47B
AUM Growth
+$318M
Cap. Flow
-$240M
Cap. Flow %
-3.22%
Top 10 Hldgs %
15.62%
Holding
988
New
245
Increased
155
Reduced
180
Closed
244

Top Buys

Rank Stock Value
1
TEL icon
TE Connectivity
TEL
+$145M
2
BKNG icon
Booking.com
BKNG
+$116M
3
EA icon
Electronic Arts
EA
+$87.6M
4
TMO icon
Thermo Fisher Scientific
TMO
+$74.1M
5
MSFT icon
Microsoft
MSFT
+$66.5M

Sector Composition

Rank Sector Weight
1 Healthcare 33.33%
2 Technology 31.02%
3 Industrials 9.63%
4 Financials 6.43%
5 Consumer Discretionary 5.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MASI
176
DELISTED
Masimo
MASI
$11.9M 0.16%
80,516
+63,017
+360% +$8.67M
WRK
177
DELISTED
WestRock Company
WRK
$11.9M 0.16%
+338,253
New +$11.8M
IAA
178
DELISTED
IAA, Inc. Common Stock
IAA
$11.9M 0.16%
+297,250
New +$11.2M
RGNX icon
179
Regenxbio
RGNX
$657M
$11.8M 0.16%
+520,635
New +$11.8M
CFLT
180
DELISTED
Confluent
CFLT
$11.8M 0.16%
529,521
+353,965
+202% +$8.2M
XENE icon
181
Xenon Pharmaceuticals
XENE
$6.13B
$11.8M 0.16%
298,440
-105,919
-26% -$3.86M
TJX icon
182
TJX Companies
TJX
$174B
$11.7M 0.16%
147,171
+13,687
+10% +$1.01M
USER
183
DELISTED
UserTesting, Inc.
USER
$11.7M 0.16%
+1,552,642
New +$9.93M
ASND icon
184
Ascendis Pharma A/S
ASND
$15.9B
$11.6M 0.16%
95,113
-116,280
-55% -$13.5M
WST icon
185
West Pharmaceutical
WST
$24.4B
$11.6M 0.16%
+49,272
New +$11.7M
EL icon
186
Estee Lauder
EL
$31.2B
$11.6M 0.15%
46,563
+30,198
+185% +$6.74M
BIDU icon
187
Baidu
BIDU
$38.2B
$11.5M 0.15%
100,640
+60,040
+148% +$6.13M
SGFY
188
DELISTED
Signify Health, Inc.
SGFY
$11.4M 0.15%
397,000
-233,300
-37% -$6.73M
PTC icon
189
PTC
PTC
$15.2B
$11.2M 0.15%
+93,398
New +$11.2M
COTY icon
190
Coty
COTY
$2.55B
$11M 0.15%
1,290,167
-267,369
-17% -$1.96M
DT icon
191
Dynatrace
DT
$13.2B
$10.8M 0.15%
+282,951
New +$10.3M
PLNT icon
192
Planet Fitness
PLNT
$4.36B
$10.8M 0.14%
137,381
-3,188
-2% -$222K
SPRY icon
193
ARS Pharmaceuticals
SPRY
$521M
$10.8M 0.14%
1,261,307
+448,408
+55% +$2.91M
RVMD icon
194
Revolution Medicines
RVMD
$40.6B
$10.7M 0.14%
450,015
-113,866
-20% -$2.42M
LITE icon
195
Lumentum
LITE
$66.5B
$10.7M 0.14%
204,726
-59,553
-23% -$3.66M
CCK icon
196
Crown Holdings
CCK
$13.1B
$10.6M 0.14%
+129,158
New +$10.3M
RCM
197
DELISTED
R1 RCM Inc. Common Stock
RCM
$10.6M 0.14%
+966,645
New +$12.3M
BPMC
198
DELISTED
Blueprint Medicines
BPMC
$10.5M 0.14%
240,694
+147,307
+158% +$7.06M
VEEV icon
199
Veeva Systems
VEEV
$34.2B
$10.4M 0.14%
+64,719
New +$11.1M
OC icon
200
Owens Corning
OC
$11.6B
$10.4M 0.14%
+122,140
New +$10.7M

Similar funds

Woodline Partners's Q4 2022 Portfolio in Review

As of Q4 2022, Woodline Partners held 988 positions worth $7.47B, up 4.4% from $7.16B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Woodline Partners withdrew a net $240M in Q4 2022, closing 244 positions and reducing 180 holdings. Its most notable exit was Amazon, an estimated $77.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 36% a quarter earlier, followed by Technology and Industrials.

Against the trend, Woodline Partners opened a new position in Booking.com worth $123M.

  • Woodline Partners's largest Q4 2022 buy was Booking.com: 1,526,600 shares worth $123M.
  • Woodline Partners added most to TE Connectivity in Q4 2022, an estimated $145M increase.
  • Woodline Partners's biggest Q4 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $169M.
  • Woodline Partners fully exited Amazon in Q4 2022, selling an estimated $77.2M.
  • Woodline Partners's ten largest holdings make up 16% of its $7.47B portfolio in Q4 2022.
  • Woodline Partners opened 245 new positions and closed 244 in Q4 2022.
  • Woodline Partners's portfolio value rose 4.4% quarter-over-quarter to $7.47B.

Based on Woodline Partners's 13F filing for Q4 2022, filed 14 Feb 2023.